Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines

Details Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines

2007-04-10

2007-04-10

Tucker, Zachary C. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C544S346000

Reexamination Certificate

active

10805885

ABSTRACT:
The present invention provides compounds of formula (I)the prodrugs thereof, and the pharmaceutically acceptable salts of the compounds and prodrugs, wherein Ra, Rb, R1, and R2are as defined herein; pharmaceutical compositions thereof; and uses thereof.

REFERENCES:
patent: 1050535 (2000-11-01), None
patent: 1295885 (2003-03-01), None
patent: WO 0250079 (2002-06-01), None
patent: WO 02083140 (2002-10-01), None
Hans Bundgaard, Design of Prodrugs, p. 1. © 1985 Elsevier Science Publishers.
Richard B. Silverman, The Organic Chemistry of Drug Design and Drug Action, pp. 352-400. © Academic Press, Inc.
Al-Dabbagh and Smith, “Species differences in oxidative drug metabolism: some basic considerations.” Archives of toxicology. Supplement. Archiv fur Toxikologie. supplement, vol. 7, pp. 219-231 (1984).
Eldar-Finkelman and Ilouz “Challenges and opportunities with glycogen synthase kinase-3 inhibitors for insulin resistance and Type 2 diabetes treatment” Expert Opinion on Investigational Drugs, vol. 12(9), pp. 1511-1519 (2003).
Martinez et al, “Glycogen Synthase Kinase 3 (GSK-3) Inhibitors as New Promising Drugs for Diabetes, Neurodegeneration, Cancer, and Inflammation” Medical Research Reviews, vol. 22(4), pp. 373-384 (2002).
Singh, P. et al., Indian Journal of Chemistry, vol. 35B, pp. 929-934, Sep. 1996, “Fujita-Ban and Hansch analyses A1- and A2-adenosine receptor binding affinities of some 4-amino[1,2,4]triazolo[4,3-α]quinoxalines.”
Sarges, R. et al., J. Med. Chem., vol. 33, pp. 2240-2254, 1990, “4-Amino[1,2,4]triazolo[4,3-α]quinoxalines. A Novel Class of Potent Adenosine Receptor Antagonists and Potential Rapid-Onset Antidepressants.”
Adenot, M. et al., Eur J Med Chem, vol. 32, pp. 493-504, 1997, “Interest of cluster significance analysis in structure-affinity relationships for non-xanthine heterocyclic antagonists of adenosine.”
Colotta, V. et al., Arch. Pharm. Pharm. Med. Chem., vol. 332, pp. 39-41, (1999), “4-Amino-6-benzylamino-1,2-dihydro-2-phenyl-1,2,4-triazolo[4,3-α]-quinoxalin-1-one: A New A2AAdenosine Receptor Antagonist with High SelectivityversusA1 Receptors.”
Colotta, V. et al., J. Med. Chem., vol. 43, pp. 1158-1164, 2000, “1,2,4-Triazolo[4,3-α]quinoxalin-1-one: A Versatile Tool for the Synthesis of Potent and Selective Adenosine Receptor Antagonists.”
Smith, David et al., 3-Anilino-4-arylmaleimides: Potent and Selective Inhibitors of Glycogen Synthase Kinase-3 (GSK-3), Pergamon Bioorganic & Medicinal Chemistry Letters 11 (2001) pp. 635-639.
Bertrand, J.A., et al., Structural Characterization of the GSK-3B Active Site Using Selective and Non-selective ATP-mimetic Inhibitors, J.Mol.Biol. (2003) 333, 393-407.

Affiliated with

Also associated with

Rating

Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3731053